Pharmafile Logo

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

January 7, 2026 | Intelligent Commercialization 

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.

Evoke-Podcast

How AI and LLMs are shaping audience intelligence in life sciences

In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.

Why real behavior and high-quality data are critical for predictive accuracy

The discussion focuses on several key themes, including: 

  • The limitations of narrow or closed data inputs and how they restrict prediction accuracy 
  • The importance of understanding real behavior beyond a single organization’s data 
  • Why high-quality, holistic data sets are essential to improving LLM performance 
  • The role of subject matter experts in providing context that general-purpose models currently lack 
  • How data quality directly influences the usefulness and reliability of AI tools 

Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement. 

Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”

Intelligent Commercialization™ in action

This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Research Partnership is UK’s fastest growing healthcare market research specialist

The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014.With turnover...

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories, our experts have produced an essential guide to help address some of the core challenges for conducting market...

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Exploring the Opportunity For Halal In Healthcare

Published in Medical Marketing & Media November 2015

Case study: Opportunity Assessment for a Rare Disease Product in Emerging Markets

Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets

12 Challenges Big Pharma Faces in China

Published in eyeforpharma 16 November by Rachel Howard

Using mobile “diary” research to capture patient-generated insights in COPD

Our latest case study demonstrates how a mobile app methodology was used to deliver key insights into issues faced by COPD patients

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Webinar: Understanding the Patient Journey in China 2015

Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and consider the possible implications for market researchers.

Understanding Patient Willingness to Pay

Published in eyeforpharma 12 October by Rachel Howard